FindTrial
Sign In

Clinical effect of rimazolam alone or in combination with dexmetomidine in the diagnosis and treatment of painless bronchoscopy and its effect on postoperative cognitive function

Clinical effect of rimazolam alone or in combination with dexmetomidine in the diagnosis and treatment of painless bronchoscopy and its effect on postoperative cognitive function

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041435
Enrollment
Unknown
Registered
2020-12-26
Start date
2021-01-31
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical effect of rimazolam alone or in combination with dexmetomidine in the diagnosis and treatment of painless bronchoscopy and its effect on postoperative cognitive function

Interventions

Propofol group:Propofol
Rimazolam group:Rimazolam
Rimazolam + dexmetomidine group:Dexmetomidine

Sponsors

Gao Shenqiang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. From November 2020 to November 2021, 90 patients underwent fiberoptic bronchoscopy in the outpatient department of Tai'an central hospital; 2. Patients aged 18-70 years old; 3. Patients with ASA grade I-III.

Exclusion criteria

Exclusion criteria: 1. Patients with hypoxemia (SpO2 = 3; 7. Patients with nervous and mental diseases; 8. Patients with long-term drug abuse; 9. Pregnant subjects; 10. Subjects who are intolerant or allergic to experimental drugs.

Design outcomes

Primary

MeasureTime frame
Cough score;The incidence of hypoxemia;—

Countries

China

Contacts

Public ContactGao Shenqiang

Tai'an Central Hospital

gaoshenqiang1979@sina.com+86 13563806165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026